| Literature DB >> 34296676 |
Esther Kissling1, Mariette Hooiveld2, Virginia Sandonis Martín3, Iván Martínez-Baz4,5, Naoma William6, Ana-Maria Vilcu7, Clara Mazagatos5,8, Lisa Domegan9, Simon de Lusignan10,11, Adam Meijer12, Ausenda Machado13, Mia Brytting14, Itziar Casado4,5, Josephine-L K Murray6, Sylvie Belhillil15,16, Amparo Larrauri5,8, Joan O'Donnell9, Ruby Tsang10,11, Marit de Lange12, Ana Paula Rodrigues13, Maximilian Riess14, Jesús Castilla4,5, Mark Hamilton6, Alessandra Falchi17, Francisco Pozo3, Linda Dunford18, Jade Cogdale19, Tessa Jansen2, Raquel Guiomar13, Theresa Enkirch14, Cristina Burgui4,5, Debbie Sigerson6, Thierry Blanchon7, Eva María Martínez Ochoa20, Jeff Connell18, Joanna Ellis19, Rianne van Gageldonk-Lafeber12, Irina Kislaya13, Angela Mc Rose1, Marta Valenciano1.
Abstract
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.Entities:
Keywords: COVID-19; Europe; SARS-CoV-2; multicentre study; test-negative design; vaccine effectiveness
Mesh：
Substances：
Year: 2021 PMID： 34296676 DOI： 10.2807/1560-7917.ES.2021.26.29.2100670
Source DB: PubMed Journal: Euro Surveill ISSN： 1025-496X